Dr. Grandjean's environmental epidemiology research focuses especially on delayed effects of developmental exposure to environmental chemicals. Studies on marine contaminants were initiated with Dr. Pal Weihe in the Faroe Islands in the mid-1980s; prospective cohort studies on almost 3,000 Faroese children first focused on neurotoxicity, but the most recent projects have also examined general development and immunotoxicity in regard to organic pollutants, such as PCBs and PFCs. The results have inspired downward revisions of methylmercury exposure limits internationally. Other recent studies have targeted age-related functional deficits and degenerative diseases, such as Parkinson's disease, cardiovascular disease, and type 2 diabetes in regard to life-time exposure to methylmercury, arsenic, persistent lipophilic contaminants, and perfluorinated compounds. Other efforts relate to biomarker development and validation, endocrine disruption caused by organochlorine substances. adverse effects of fluoride exposure, and the neurotoxicity of lead. Dr. Grandjean has also published on research ethics, genetic susceptibility, the setting of exposure limits, and the impact of the precautionary principle on prevention and research.
Appendix to "Developmental Neurotoxicity of Industrial Chemicals" (The Lancet, 2006)
Conference statement on developmental programming (2008)
The Matthew effect in environmental science publishing (2011)
